FONAR Corporation

NASDAQ:FONR

Medical - Devices

Healthcare
$19.09 +0.00%

+$0.00 today

Market cap
$117.76M
Beta
0.95
P/E (TTM)
17.6
EPS (TTM)
$1.08
52W Low $13.62High $19.16

Volume 0.00M

Average 0.08M

FONR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

FONAR CorporationNASDAQ: FONR

Research & Development · Q3 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $424K fell 3.9% year over year, behind the +13.3% change in trailing-twelve-month research & development. Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.

Context

  • Research & development amounted to 1.5% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -3.9% toward the trailing-twelve-month pace of +13.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$424K-6.8% QoQ
Last fiscal yearJun 2025
$1.58M-9.2% YoY
LTMMar 2026
$1.77M+13.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.9%——
1 year-9.2%——
3-year CAGR+1.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
1.58M USD
Year-over-year change
-9.2%
4-year CAGR
-0.9%

Research & Development vs competitors

How FONR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.3% is the 2nd highest of 8, against a peer median of -5.9%.
  • Research & development amounts to 1.7% of revenue for FONR, versus a peer median of 27.9%.
FONR Competitors
Research & Development for FONR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$71.8M USD+27.7%+16.5%—
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M USD-5.9%+14.6%27.9%
LUNGPulmonx CorporationLTM Mar 2026$19.63M USD+8.4%+8.2%22.2%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M USD+11.9%+8.6%—
HYPRHyperfine, Inc.LTM Mar 2026$16.26M USD-26.0%-14.7%106.1%
APYXApyx Medical CorporationLTM Mar 2026$3.33M USD-25.7%-9.5%6.0%
FONRFONAR CorporationLTM Mar 2026$1.77M USD+13.3%+1.8%1.7%
Peer median (excluding FONR) —-5.9%+8.2%27.9%

Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue89.93M97.59M98.65M102.88M104.35M
Cost of Revenue46.46M50.58M52.9M57.74M61.44M
Gross Profit43.47M47.01M45.75M45.14M42.91M
Gross Margin48.3%48.2%46.4%43.9%41.1%
Research & Development1.64M1.49M1.57M1.74M1.58M
Selling, General & Admin0029.39M029.73M
Operating Expenses26.38M25.01M30.96M28.6M31.31M
Depreciation & Amortization4.08M4.54M8.8M4.6M4.7M
EBITDA22M27.65M24.61M23.94M18.5M
EBITDA Margin24.5%28.3%25.0%23.3%17.7%
Operating Income17.1M22.01M14.79M16.54M11.6M
Operating Margin19.0%22.6%15.0%16.1%11.1%
Interest Income00002.17M
Interest Expense248.67K346.55K50.13K77K25.61K
Other Income / Expenses567.72K761.69K969.33K2.73M2.18M
Income Before Tax17.67M22.77M15.76M19.27M13.78M
Pre-Tax Margin19.6%23.3%16.0%18.7%13.2%
Income Tax Expense3.99M5.53M3.63M5.17M3.11M
Net Income10.21M12.44M9.38M10.57M8.33M
Net Margin11.4%12.7%9.5%10.3%8.0%
EPS (Basic)1.471.781.351.561.26
EPS (Diluted)1.451.751.321.531.23
Weighted Avg Shares6.61M6.55M6.65M6.35M6.32M
Weighted Avg Shares (Diluted)6.74M6.68M6.77M6.48M6.55M

FONAR Corporation

NASDAQ:FONR

Intrinsic Alpha fair value

Locked

Current Price

$19.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.